Mediators of Inflammation / 2013 / Article / Tab 2

Clinical Study

Eosinophil-Derived Neurotoxin Is Elevated in Patients with Amyotrophic Lateral Sclerosis

Table 2

The concentrations of EDN and ECP in sera from patients with ALS, AD, and PD and from controls.

Group ( ) EDNaECPa
mean (SD, range)mean (range)

P valueP value
ControlADPDALSControlADPDALS

Control (44)21.0 (14.9, 8.6–79.4)21.1 (27.4, 1.7–109.9)
AD (39)28.3 (36.6, 1.9–158.0)0.2315.4 (17.4, 0–97.1)0.26
PD (40)24.8 (20.7, 3.1–95.5)0.330.6115.8 (15.2, 0–77.8)0.270.73
ALS (44)45.7 (29.3, 8.9–140.9)<0.0050.010.0224.1 (24.5, 0.4–88.8)0.060.070.06

bALSFRS-R P valueP value
Control0–910–1920–2930–3940–47Control0–910–1920–2930–3940–47

0–9 (15)42.6 (27.6, 11.9–99.9)0.6318.7 (19.1, 4.3–77.7)0.60
10–19 (11)45.9 (37.5, 8.9–140.9)0.170.2425.6 (27.4, 4.3–78.4)0.430.71
20–29 (7)39.9 (21.1, 14.6–69.7)0.080.590.9021.6 (22.5, 6.3–66.3)0.200.500.91
30–39 (7)51.3 (25.8, 17.9–89.3)0.270.350.660.4926.2 (27.6, 0.4–77.5)0.350.660.170.96
40–47 (4)57.4 (37.6, 18.3–108.7)0.750.750.330.330.9240.9 (35.4, 12.1–88.8)0.420.750.330.330.42

cDuration P valueP value
Control1–1213–2425–36>37Control1–1213–2425–36>37

1–12 (31)50.3 (32.7, 8.9–140.9)0.8318.9 (20.3, 4.3–77.4)0.75
13–24 (8)31.3 (12.2, 16.6–48.6)0.130.2732.5 (31.2, 4.3–88.8)0.880.70
25–36 (3)49.0 (15.1, 33.2–50.2)NA fNANA58.5 (24.1, 31.5–77.7)NANA0.33
>37 (2)27.9 (13.2, 18.6–37.3)NANANANA18.4 (17.1, 6.3–30.5)NANANANA

dAge P valueP value
Control41–5051–6061–7071–80Control41–5051–6061–7071–80

41–50 (7)58.9 (42.2, 20.9–140.9)0.3040.7 (30.6, 10.9–78.4)0.56
51–60 (19)35.8 (21.2, 8.9–101.8)0.060.4919.3 (21.1, 4.3–77.7)0.820.56
61–70 (13)53.5 (30.2, 14.6–108.7)0.480.440.9165.4 (26.3, 6.4–88.8)0.720.570.93
71–80 (5)45 (28.1, 16.6–83.4)0.450.950.450.359.9 (7.8, 0.4–20)0.780.450.680.35

eOnset type P valueP value
ControlBrainstemHandFootControlBrainstemHandFoot

Brainstem (13)42.4 (25.2, 14.6–99.9)0.8919.8 (21.9, 4.3–77.7)0.54
Hand (12)51.1 (30.9, 8.9–108.7)0.680.5422.9 (28.7, 6.2–77.5)0.900.86
Foot (19)44.7 (32.3, 11.9–140.9)0.920.880.6227.7 (20.4, 0.42–88.8)0.390.460.39

aConcentrations are expressed as ng/mL.
bALSFRS-R is a score from 0 to 48 which assesses disability in patients with motor neuron diseases. 0 means serious, and 48 means normal.
cCategories are based on the duration of symptoms (months).
dCategories indicate age at time of blood collection (years).
eCategories indicate the type of onset.
fThe NA were divided according to the unanalyzable group (sample number of subgroup <3).
The one-way ANOVA test and Bonferroni multiple comparison test were used to determine the significance among the test groups of control, AD, PD, and ALS.
The Spearman rank correlation test was used to correlate the levels of EDN and ECP versus the subgroups of age, ALSFRS-R, duration, and onset types.